Fig. 2

Kaplan-Meier curves according to Reti-CVD in borderline-QRISK3 group. Cardiovascular disease (CVD) event rate according to Reti-CVD-three groups in borderline-QRISK3 group who had QRISK3 score between 7.5 and 10% were presented in non-statin cohort (A), stage 1 hypertension cohort (B), and middle-aged (40–64 years) cohorts (C). Considering that statin and antihypertensive pharmacotherapy initiation is recommended at QRISK of ≥ 10%, Reti-CVD can be used as a risk enhancer in borderline-QRISK3 groups of 7.5–10% to reach consensus on statin initiation. In addition, although most of risk assessment systems were derived from cohorts of primarily middle-aged people and typically well-functioning individuals, Reti-CVD can still be a risk enhancer in in borderline-QRISK3 groups of 7.5–10% middle-aged people